Neurological Disorders
BOSTON SCIENTIFIC LAUNCHES VERCISE GENUS™ DBS SYSTEM IN EUROPE-
Sept 10, 2020
Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the fourth generation Vercise Genus™ Deep Brain Stimulation (DBS) System in Europe. Featuring full-body MRI conditionaland Bluetooth capabilities across the portfolio…
Boston scientific announces CE mark approval of the Vercise™ Neural Navigator 3 Programming Software -
Oct 17, 2019
Boston Scientific Corporation announced the CE Mark approval of the Vercise™ Neural Navigator 3 directional Deep Brain Stimulation (DBS) programming software - the first system that integrates patient-specific 3D brain anatomy and…
Boston Scientific launches GUIDE™ XT System for Visualization of Deep Brain Stimulation - Sep 26, 2018
Boston Scientific Corporation today announced the launch of the GUIDE™ XT System for visualization of Deep Brain Stimulation (DBS) in Europe. The GUIDE XT System is the first DBS visualization system built for…
SEE ALL PRESS RELEASES
BOSTON SCIENTIFIC LAUNCHES VERCISE GENUS™ DBS SYSTEM IN EUROPE-
Sept 10, 2020
Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the fourth generation Vercise Genus™ Deep Brain Stimulation (DBS) System in Europe. Featuring full-body MRI conditionaland Bluetooth capabilities across the portfolio…
BOSTON SCIENTIFIC LAUNCHES WAVEWRITER ALPHA™ SPINAL CORD STIMULATOR SYSTEMS IN EUROPE-
SCS portfolio features full-body MRI conditional devices that combine therapy options for personalized pain relief
Sept 30, 2020
Boston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems. The portfolio, consisting of four MRI conditionali, Bluetooth-enabled implantable pulse generators (IPGs), offers expanded personalization based on patient needs, including rechargeable and non-rechargeable options, and access to waveforms that can cover multiple areas of pain…
Media Contacts
Rosie Ireland
Corporate Communications
+44 7585403359
rosie.ireland@bsci.com